Sean P. Brusky
Fortune : 392 000 $ au 31/05/2026
Fortune : 392 000 $ au 31/05/2026
Sean P.
Brusky is Chief Business Officer at Prelude Therapeutics, Inc. since 2024.
Mr. Brusky is Chief Commercial Officer at Pardes Biosciences, Inc. since 2021.
Former roles include Head-Healthcare Delivery Innovation at Genentech, Inc. and Manager-Business & Corporate Development at Vertex Pharmaceuticals, Inc. from 2001 to 2004.
Education includes undergraduate studies at Brown University and an MBA from Harvard Business School.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 05/03/2026 | 100 000 ( 0,15% ) | 392 000 $ | 31/05/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| PRELUDE THERAPEUTICS INCORPORATED | Corporate Officer/Principal | 01/04/2024 |
| Sociétés | Poste | Fin |
|---|---|---|
| VERTEX PHARMACEUTICALS INCORPORATED | Corporate Officer/Principal | 01/08/2004 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Corporate Officer/Principal | - |
| PARDES BIOSCIENCES, INC. | Corporate Officer/Principal | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 6 |
|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Health Technology |
Vertex Pharmaceuticals, Inc.
Vertex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops drugs for the treatment of cystic fibrosis | Health Technology |
Brown University
Brown University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Harvard Business School
Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Prelude Therapeutics, Inc.
Prelude Therapeutics, Inc. BiotechnologyHealth Technology Discovers and develops medicines targeting chromatin function to treat cancer and rare diseases | Health Technology |
Pardes Biosciences, Inc.
Pardes Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops oral antiviral treatment for COVID-19 | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national